Publication Name	World Journal of Clinical Cases
Manuscript ID	58331
Country	Taiwan

Category	Urology & Nephrology
Manuscript Type	Case Report
Article Title	Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Che Hseuh Yang, Kuo Tung Chen, Yi Sheng Lin, Chao Yu Hsu, Yen Chuan Ou and Min Che Tung
Funding Agency and Grant Number
Corresponding Author	Yi Sheng Lin, MD, Attending Doctor, Surgeon, Surgical Oncologist, Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, No. 699 Sec. 8, Taiwan Blvd., Wuqi Dist., Taichung City 435403, Taiwan. tung12197@gmail.com
Key Words	Molecular targeted therapy/methods; Receptors; Vascular endothelial growth factor/drug effects; Vascular endothelial growth factor/therapeutic use; Vascular endothelial growth factor A/drug effects; Nephrotic syndrome/drug therapy
Core Tip	Trials of anti-vascular endothelial growth factor (VEGF) therapy mostly focused on drugs with more potent to its receptors and with better progression-free survival, but few reports discussed about nephrotoxicity induced by anti-VEGF drugs, especially achieving improvement by regimens’ adaptions. This study is the second published case report about the successful adaption from lenvatinib, a more potent tyrosine kinase inhibitor (TKI), to sorafenib, a less potent TKI, to improve the nephrotoxicity and, meanwhile, achieve the therapeutic goal of cancer control.
Citation	Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report. World J Clin Cases 2020; 8(20): 4883-4894

Received	2020-07-17 15:12
Peer-Review Started	2020-07-17 15:13
To Make the First Decision
Return for Revision	2020-08-22 23:26
Revised	2020-08-28 14:51
Second Decision	2020-09-15 12:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-09-15 23:53
Articles in Press	2020-09-15 23:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-10-21 06:58

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com